SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ibraghimov-Beskrovnaya, O., Ervasti, J. M., Leveille, C. J., Slaughter, C. A., Sernett, S. W., et al. ( 1992) Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 355, 696702.
  • 2
    Bozzi, M., Morlacchi, S., Bigotti, M. G., Sciandra, F., and Brancaccio, A. ( 2009) Functional diversity of dystroglycan. Matrix Biol. 28, 179187.
  • 3
    Henry, M. D. and Campbell, K. P. ( 1999) Dystroglycan inside and out. Curr. Opin. Cell Biol. 11, 602607.
  • 4
    Barresi, R. and Campbell, K. P. ( 2006) Dystroglycan: from biosynthesis to pathogenesis of human disease. J. Cell Sci. 119, 199207.
  • 5
    Court, F. A., Zambroni, D., Pavoni, E., Colombelli, C., Baragli, C., et al. ( 2011) MMP2-9 cleavage of dystroglycan alters the size and molecular composition of Schwann cell domains. J. Neurosci. 31, 1220812217.
  • 6
    Sgambato, A. and Brancaccio, A. ( 2005) The dystroglycan complex: from biology to cancer. J. Cell Physiol. 205, 163169.
  • 7
    Agrawal, S., Anderson, P., Durbeej, M., van Rooijen, N., Ivars, F., et al. ( 2006) Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J. Exp. Med. 203, 10071019.
  • 8
    Michaluk, P., Kolodziej, L., Mioduszewska, B., Wilczynski, G. M., Dzwonek, J., et al. ( 2007) β-Dystroglycan as a target for MMP-9, in response to enhanced neuronal activity. J. Biol. Chem. 282, 1603616041.
  • 9
    Zhao, X. L., Li, G. Z., Sun, B., Zhang, Z. L., Yin, Y. H., et al. ( 2010) MMP-mediated cleavage of β-dystroglycan in myelin sheath is involved in autoimmune neuritis. Biochem. Biophys. Res. Commun. 392, 551556.
  • 10
    Losasso, C., Di Tommaso, F., Sgambato, A., Ardito, R., Cittadini, A., et al. ( 2000) Anomalous dystroglycan in carcinoma cell lines. FEBS Lett. 484, 194198.
  • 11
    Zhong, D., Saito, F., Saito, Y., Nakamura, A., Shimizu, T., et al. ( 2006) Characterization of the protease activity that cleaves the extracellular domain of β-dystroglycan. Biochem. Biophys. Res. Commun. 345, 867871.
  • 12
    Nagase, H. and Woessner, J. F.,Jr. ( 1999) Matrix metalloproteinases. J. Biol. Chem. 274, 2149121494.
  • 13
    Van den Steen, P. E., Dubois, B., Nelissen, I., Rudd, P. M., Dwek, R. A., et al. ( 2002) Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit. Rev. Biochem. Mol. Biol. 37, 375536.
  • 14
    Li, H., Mittal, A., Makonchuk, D. Y., Bhatnagar, S., and Kumar, A. ( 2009) Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. Hum. Mol. Genet. 18, 25842598.
  • 15
    Sbardella, D., Fasciglione, G. F., Gioia, M., Ciaccio, C., Tundo, G. R., et al. ( 2012) Human matrix metalloproteinases: an ubiquitarian class of enzymes involved in several pathological processes. Mol. Aspects Med. 33, 119208.
  • 16
    Björklund, M. and Koivunen, E. ( 2005) Gelatinase-mediated migration and invasion of cancer cells. Biochim. Biophys. Acta 1755, 3769.
  • 17
    Bozzi, M., Inzitari, R., Sbardella, D., Monaco, S., Pavoni, E., et al. ( 2009) Enzymatic processing of β-dystroglycan recombinant ectodomain by MMP-9: identification of the main cleavage site. IUBMB Life 61, 11431152.
  • 18
    Bozzi, M., Veglia, G., Paci, M., Sciandra, F., Giardina, B., et al. ( 2001) A synthetic peptide corresponding to the 550–585 region of α-dystroglycan binds β-dystroglycan as revealed by NMR spectroscopy. FEBS Lett. 499, 210214.
  • 19
    Bozzi, M., Sciandra, F., Ferri, L., Torreri, P., Pavoni, E., et al. ( 2006) Concerted mutation of Phe residues belonging to the β-dystroglycan ectodomain strongly inhibits the interaction with α-dystroglycan in vitro. FEBS J. 273, 49294943.
  • 20
    Di Stasio, E., Sciandra, F., Maras, B., Di Tommaso, F., Petrucci, T. C., et al. ( 1999) Structural and functional analysis of the N-terminal extracellular region of β-dystroglycan. Biochem. Biophys. Res. Commun. 266, 274278.
  • 21
    Van den Steen, P. E., Van Aelst, I., Hvidberg, V., Piccard, H., Fiten, P., et al. ( 2006) The hemopexin and O-glycosylated domains tune gelatinase B/MMP-9 bioavailability by inhibition and binding to cargo receptors. J. Biol. Chem. 281, 1862618637.
  • 22
    Gioia, M., Monaco, S., Fasciglione, G. F., Coletti, A., Modesti, A., et al. ( 2007) Characterization of the mechanism by which gelatinase A, neutrophil collagenase and membrane-type metalloproteinase MMP-14 recognize collagen I and enzymatically process the two α-chains. J. Mol. Biol. 368, 11011113.
  • 23
    Gioia, M., Monaco, S., Van den Steen, P. E., Sbardella, D., Grasso, G., et al. ( 2009) The collagen binding domain of gelatinase A modulates degradation of collagen IV by gelatinase B. J. Mol. Biol. 386, 419434.
  • 24
    Ong, S. E. and Mann, M. ( 2005) Mass spectrometry-based proteomics turns quantitative. Nat. Chem. Biol. 1, 252262.
  • 25
    Van den Steen, P. E., Proost, P., Grillet, B., Brand, D. D., Kang, A. H., et al. ( 2002) Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, post-translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis. FASEB J. 16, 379389.
  • 26
    Chen, E. I., Li, W., Godzik, A., Howard, E. W., and Smith, J. W. ( 2003) A residue in the S2 subsite controls substrate selectivity of matrix metalloproteinase-2 and matrix metalloproteinase-9. J. Biol. Chem. 278, 1715817163.
  • 27
    Overall, C. M. and Butler, G. S. ( 2007) Protease yoga: extreme flexibility of a matrix metalloproteinase. Structure 15, 11591161.
  • 28
    Rosenblum, G., Van den Steeen, P. E., Cohen, S. R., Grossmann, J. G., Frenkel, J., et al. ( 2007) Insight into the structure and domain flexibility of full-length pro-matrix metalloproteinase-9/gelatinase B. Structure 15, 12271236.
  • 29
    Moore, C. J. and Winder, S. J. ( 2010) Dystroglycan versatility in cell adhesion: a tale of multiple motifs. Cell Commun. Signal. 8, 314.